ReviewCurrent gastroenterology reports2019
Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.
Review in Current gastroenterology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- In Vivo Studies on the Interaction Between Orally Administered Nitrite and Omeprazole: Beyond Proton-Catalyzed S-Nitrosation.Antioxidants (Basel, Switzerland) · 2025Article
- Proton Pump Inhibitor Use in Older Adult Patients with Multiple Chronic Conditions: Clinical Risks and Best Practices.Journal of clinical medicine · 2025Review
- Age-Related Decline of Gastric Secretion: Facts and Controversies.Biomedicines · 2025Review
- Chinese expert consensus on diagnosis and management of gastroesophageal reflux disease in the elderly (2023).Aging medicine (Milton (N.S.W)) · 2024Article
- Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study.European journal of clinical pharmacology · 2023Article
- Inappropriate proton pump inhibitor lansoprazole prescription in older adults hospitalized in long-term care unit.Irish journal of medical science · 2023Article
- Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers.BMC geriatrics · 2022Article
- Treating and Managing Laryngopharyngeal Reflux Disease in the Over 65s: Evidence to Date.Clinical interventions in aging · 2022Review
- The inappropriate use of proton pump inhibitors and its associated factors among community-dwelling older adults.Heliyon · 2021Article
- Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data.International journal of environmental research and public health · 2021Article
- Proton Pump Inhibitors Increase the Risk of Autoimmune Diseases: A Nationwide Cohort Study.Frontiers in immunology · 2021Observational
- Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.Drugs & aging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewProton pump inhibitors (PPIs) are one of the most prescribed drugs in the developed world and elderly patients are particularly likely to be prescribed acid suppression. There have been reports of many diseases being associated with PPI therapy and the elderly would be particular at risk of any harms these drugs may cause. This review therefore reviews the evidence of the risks and benefits of these drugs. RECENT
findingsPPIs are very effective at treating acid-related disorders. Recent randomized trials have suggested that the associations between PPI and various diseases are likely to be related to bias and residual confounding and these drugs appear to be safe apart from a possible increase risk of enteric infections. PPIs should be used at the lowest dose and for the shortest duration possible. They are still relatively safe drugs but should only be prescribed for proven indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.